Any current/future new fundraising through debt or equity?

As per the discussion on Page 15, the company currently plans only maintenance capital expenditure (capex) for the next 2 years and does not anticipate major new capex. Management aims to reduce debt by around INR 100 crores annually from a peak net debt of approximately INR 830 crores (March balance sheet). There is no mention of any plans for new fundraising through debt or equity in the near term. The focus is on debt reduction and managing working capital efficiently. No plans for share buyback have been indicated, and any surplus cash generated will be primarily used for debt repayment. F

Any current/future capex/capital investment/strategic investment?

No major new capex planned for the next 2 years; only maintenance capex is expected (Page 15). Recent greenfield capex of around INR 390 crores in benzene derivatives, including infrastructure and land, has started commercial production but currently operating at low volumes due to technology synchronization issues (Pages 10, 11). Expansion plans or new capex on benzene downstream/derivatives side will be reconsidered after 2 years based on business scenarios (Page 15). Management's focus is on reducing debt by approx. INR 100 crores annually, with net debt expected to decline from INR 830 cro

Future growth expectations in sales/revenue/volumes?

Dye Intermediates and Dyestuffs volumes expected to remain flattish; limited scope for major volume increase due to batch-type manufacturing and current near-peak utilization (~80-90%). Some room for improvement in Dyestuff volumes, but not substantial in Dye Intermediates. Company focusing on diversification beyond Dye Intermediates and Dyestuffs for future growth. Chlor Alkali business utilization expected to rise from current ~82-83% to around 90%, contributing to top-line and margin improvement. Total revenue guidance for FY '25 estimated between INR1,600 crores to INR1,800 crores, driven

Future growth expectations in earnings/operating earnings/profits/EPS?

FY '25 revenue expected to be in the range of INR1,700 to INR1,800 crores, driven by stable volumes and the addition of benzene downstream business. EBITDA guidance for FY '25 is around 10-12%, with anticipated recovery from previous levels. EBITDA expected in the range of INR160 to INR200 crores (including other income). Company expects steady debtor days and working capital improvements to aid cash flow. Efforts to close economically non-viable plants and gain government incentives (~INR20 crores annually) are expected to improve profitability. Dye Intermediates and Dyestuffs volum

IN US

Sale is live|00:00:00left today

Bodal Chemicals LtdQ1 FY24Chemicals & Petrochemicals

Bodal Chemicals Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹66.3P/E: 30.4Market Cap: ₹921 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Dye Intermediates and Dyestuffs volumes expected to remain flattish; limited scope for major volume increase due to batch-type manufacturing and current near-peak utilization (~80-90%).
→Some room for improvement in Dyestuff volumes, but not substantial in Dye Intermediates.
→Company focusing on diversification beyond Dye Intermediates and Dyestuffs for future growth.
→Chlor Alkali business utilization expected to rise from current ~82-83% to around 90%, contributing to top-line and margin improvement.
→Total revenue guidance for FY '25 estimated between INR1,600 crores to INR1,800 crores, driven by stable volumes and addition of new benzene derivatives business.
→EBITDA margin targeted around 10-12% with expected recovery from cost rationalizations and government incentives.
→Management anticipates maintaining improved working capital with debtor days stabilized.
→Near-term volume growth limited; focus on operational efficiency and portfolio expansion to sustain growth.

Margin guidance

Category 3

→FY '25 revenue expected to be in the range of INR1,700 to INR1,800 crores, driven by stable volumes and the addition of benzene downstream business.
→EBITDA guidance for FY '25 is around 10-12%, with anticipated recovery from previous levels.
→EBITDA expected in the range of INR160 to INR200 crores (including other income).
→Company expects steady debtor days and working capital improvements to aid cash flow.
→Efforts to close economically non-viable plants and gain government incentives (~INR20 crores annually) are expected to improve profitability.
→Dye Intermediates and Dyestuffs volumes likely to remain flattish; however, some marginal improvement in Dyestuffs possible.
→Chlor Alkali business utilization has room to improve (from 82-83% to 90%+), which will positively impact margins (16-20%) and top line (~INR350-370 crores revenue at peak).
→Management’s focus on diversified portfolio (including pharma and agrochemicals) aims for more stable and improved earnings over time.
→Debt reduction plan targeting INR100 crores reduction per year, improving financial health and enabling renewed dividend payments.

3 more insights locked — sign up free to unlock

Fundraise plans

→As per the discussion on Page 15, the company currently plans only maintenance capital expenditure (capex) for the next 2 years and does not anticipate major new capex.
→Management aims to reduce debt by around INR 100 crores annually from a peak net debt of approximately INR 830 crores (March balance sheet).
→There is no mention of any plans for new fundraising through debt or equity in the near term.
→The focus is on debt reduction and managing working capital efficiently.
→No plans for share buyback have been indicated, and any surplus cash generated will be primarily used for debt repayment.
→Future decisions regarding capex or fundraising will be considered after 2 years depending on business conditions (Page 15).

Order book

The transcript provided does not explicitly mention the current or expected order book or pending orders for Bodal Chemicals Limited. However, some relevant insights related to demand and business outlook include: - The company has witnessed a stable demand and gradual recovery in the last few months. - Sen-er Boya (Turkey subsidiary) is facing challenges due to the post-earthquake scenario and hyperinflation, affecting volume recovery. - Overall demand is expected to remain grim for a short period but long-term growth in India’s chemical industry remains intact. - The company expects top-line for FY25 in the range of INR 1600-1800 crores, reflecting anticipated recovery. - Focus is on improving volumes with stable utilization rates (~85% in Chlor Alkali and 80% in Dyestuffs/Dye intermediates). - No explicit details on orderbook or pending orders were disclosed in the transcript.

Capex plans

→No major new capex planned for the next 2 years; only maintenance capex is expected (Page 15).
→Recent greenfield capex of around INR 390 crores in benzene derivatives, including infrastructure and land, has started commercial production but currently operating at low volumes due to technology synchronization issues (Pages 10, 11).
→Expansion plans or new capex on benzene downstream/derivatives side will be reconsidered after 2 years based on business scenarios (Page 15).
→Management's focus is on reducing debt by approx. INR 100 crores annually, with net debt expected to decline from INR 830 crores (Page 15).
→No plans for buyback or surplus fund deployment; surplus funds are used for debt repayment (Page 12).
→Emphasis on diversifying business beyond dye intermediates and dyestuffs towards specialty chemicals like benzene derivatives (Pages 6, 14).

How does Bodal Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Bodal Chemicals Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Bodal Chemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio